The Latest Analyst Ratings for Kinnate Biopharma
Portfolio Pulse from Benzinga Insights
Kinnate Biopharma (NASDAQ:KNTE) has received mostly bullish analyst ratings in the last quarter, with an average 12-month price target of $21.04, representing an 8.52% decrease from the previous average price target of $23.00.
June 08, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kinnate Biopharma has received mostly bullish analyst ratings, with an average 12-month price target of $21.04, down 8.52% from the previous target.
The majority of analyst ratings for Kinnate Biopharma are bullish, indicating a positive outlook for the stock. The average 12-month price target has decreased by 8.52%, but it still suggests potential upside for the stock. This information is relevant and important for investors, as it provides insight into the stock's potential performance and the sentiment of industry experts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100